Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

A new study has compared Wegovy and Zepbound head-to-head in their ability to treat obesity. People taking Eli Lilly’s obesity drug Zepbound lost nearly 50% more weight than those using rival Novo ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

A new report from health data firm Truveta shows there was 50 per cent increase in American teenagers using the weight-loss drug Wegovy, particularly those living with obesity.

Participants who are taking GLP-1 medications and have taken them for at least 3 months are needed for a study on eating behavior.

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention.